Outlook Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Outlook Therapeutics, Inc. (OTLK), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on August 13, 2021. The filing serves to announce the Company's financial results for the third fiscal quarter ended June 30, 2021.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a press release (Exhibit 99.1) containing the detailed financial results but does not include the data within the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are detailed in this filing text. The document solely acts as a notification of the release of Q3 2021 results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 and the accompanying press release is not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2021) for actual Q3 2021 financial figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols OTLK (Common Stock) and OTLKW (Series A Warrants) on The Nasdaq Stock Market LLC.
- Check subsequent filings for any updates to the financial data referenced in this 8-K.